In 2005, Dr. Delmonico was elected president of the United Network of Organ Sharing/Organ Procurement Transplant Network (UNOS/OPTN) after 2 decades of UNOS committee leadership.
As the Director of Medical Affairs (DMA) of TTS, Dr. Delmonico convened transplant professionals, legal scholars, and ethicists to draft the ground-breaking Declaration of Istanbul (DOI) in 2008. This international policy document defined organ trafficking and transplant tourism, called for the equitable distribution of deceased donor organs and for the safety of transplant recipients and the wellbeing of living donors. The DOI is perhaps one of the most influential documents to standardize practices in the history of transplantation. Dr. Delmonico also collaborated with the World Health Organization (WHO) to develop WHO Guiding Principles of practice, subsequently adopted by the World Health Assembly.
Dr. Delmonico served as Chief Medical Officer of New England Donor Services, formerly New England Organ Bank (NEOB), for 25 years. His local and national leadership has been profound in establishing the medical suitability of organs derived from deceased donors. Dr. Delmonico also initiated the first regional program of paired kidney donation in the United States in 2000 under the auspices of the NEOB.
In 2016, Dr. Delmonico was appointed by Pope Francis to the Pontifical Academy of Sciences following his nomination by Nobel Laureate Joseph Murray.
Dr. Delmonico served as president of The Transplantation Society from 2012-2014.
For more than three decades, Dr. Jordan has focused his research on the immunology of antibody rejection and development of novel immune modulatory therapies to combat this condition. His professional life has been dedicated to improving transplantation rates for highly sensitized HLA and ABO blood group incompatible transplant recipients.
In 1990, Dr. Jordan developed the first desensitization protocol to reduce harmful anti-HLA antibodies. This evolved into three NIH-funded UO1 Controlled Clinical Trials. His work resulted in the approval of IVIG as a desensitization agent by Medicare in the United States. He subsequently undertook clinical trials assessing the utility of rituximab and IVIG as desensitization agents. This work also resulted in approval of this combination for treatment of highly-HLA sensitized patients.
In 2004, he developed the Transplant Immunotherapy Program at Cedars-Sinai. This program evolved to provide state-of-the-art therapies for difficult-to-transplant patients and for the development of investigator-initiated trials aimed at prevention and treatment of antibody rejection.
Dr. Jordan is currently overseeing important discovery trials to attempt to establish therapies for difficult-to-manage sensitized patients. His group currently has 16 investigator-initiated clinical trials examining novel therapies for desensitization and treatment of antibody-mediated rejection.
His work has been funded by the NIH and grants from biotechnology firms aimed at developing novel therapies in transplant medicine. He has published more than 400 peer reviewed manuscripts and book chapters.